

ASX Market Announcement



Results of Annual General Meeting

Melbourne, Australia, 28 November 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in guideline driven genomics-based tests in health, wellness and serious disease.

In accordance with ASX Listing Rule 3.13.2 & section 251AA of the Corporations Act, the following information is provided to the ASX in relation to the resolutions passed by the shareholders of Genetic Technologies Limited ('Company'), at its Annual General Meeting of shareholders held on 28 November, 2022.

All resolutions put to the meeting were passed on a poll, called by the Chairman pursuant to the Notice of Meeting.

A summary of the Poll voting results is set out on the following page.

Tony Di Pietro
Company Secretary
On behalf of the Board of Directors
Genetic Technologies Limited
+61 3 8412 7000
28 November 2022

Authorised for release by the board of directors of Genetic Technologies Limited

Enquiries

Investor Relations

Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) was founded in 1989. A global leader in guideline driven genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. In addition to our patented GeneType polygenic based risk tests, our portfolio includes pharmacogenomics, Non-Invasive Prenatal Testing (NIPT), carrier screen testing, oncogenetic diseases, and pet care.

GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company's patented Polygenic Risk Scores (PRS) platform is a proprietary risk stratification tool developed over the past decade integrating clinical and genetic risk delivering actionable outcomes for physicians and individuals. Sporadic disease occurs in people with no family history of that disease and with no inherited change in their DNA making the risk difficult to predict with traditional methods.

Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. The recent introduction of geneType Multi-Risk test risk assessments in one test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, first in class test can predict a person's risk in up to 70% of annual mortalities and morbidities before onset. These tests along with integration of recently acquired DNA based products underpin a broad and complementary portfolio of genomic based tests creating a significant competitive advantage.

For more information, please visit www.genetype.com

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of the Remuneration Report	Ordinary	541,123,404 83.28%	101,153,924 15.57%	7,467,502 1.15%	85,254,478	550,843,706 84.49%	101,153,924 15.51%	85,254,478	Carried
2 Re-Election of Mr Nick Burrows	Ordinary	739,948,815 86.65%	105,946,465 12.41%	7,977,502 0.94%	83,645,835	764,133,880 87.82%	105,946,465 12.18%	83,645,835	Carried
3 Approval of Increased Placement Capacity	Special	783,009,659 83.84%	142,988,184 15.31%	7,967,502 0.85%	3,553,272	807,184,724 84.95%	142,988,184 15.05%	3,553,272	Carried
4 Amendment to the Constitution	Special	696,223,379 83.82%	126,326,114 15.21%	8,074,645 0.97%	106,894,479	720,102,787 85.08%	126,326,114 14.92%	107,297,279	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.